SI-BONE To Present at BofA Securities 2025 Healthcare Conference on May 13, 2025
SI-BONE Inc (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, has announced its participation in the 2025 BofA Securities Healthcare Conference in Las Vegas. The company's management will conduct a fireside chat on May 13, 2025, at 8:40 AM PT/11:40 AM ET. Investors can access the live webcast through a registration link or the company's website investor section. The webcast recording will remain available for replay for at least 90 days following the event.
SI-BONE Inc (Nasdaq: SIBN), un'azienda di dispositivi medici specializzata in disturbi sacropelvici, ha annunciato la sua partecipazione alla Conferenza Sanitaria BofA Securities 2025 a Las Vegas. Il management dell'azienda terrà una chiacchierata informale il 13 maggio 2025, alle 8:40 AM PT/11:40 AM ET. Gli investitori potranno seguire la diretta streaming tramite un link di registrazione o nella sezione investitori del sito web aziendale. La registrazione della diretta sarà disponibile per la visione on demand per almeno 90 giorni dopo l'evento.
SI-BONE Inc (Nasdaq: SIBN), una empresa de dispositivos médicos enfocada en trastornos sacropélvicos, ha anunciado su participación en la Conferencia de Salud de BofA Securities 2025 en Las Vegas. La dirección de la compañía llevará a cabo una charla informal el 13 de mayo de 2025 a las 8:40 AM PT/11:40 AM ET. Los inversores podrán acceder a la transmisión en vivo a través de un enlace de registro o en la sección de inversores del sitio web de la empresa. La grabación estará disponible para reproducción durante al menos 90 días después del evento.
SI-BONE Inc (나스닥: SIBN)은 천골골반 질환에 중점을 둔 의료기기 회사로서, 라스베이거스에서 열리는 2025 BofA Securities 헬스케어 컨퍼런스에 참여할 것이라고 발표했습니다. 회사 경영진은 2025년 5월 13일 오전 8:40 PT/오전 11:40 ET에 간담회를 진행할 예정입니다. 투자자들은 등록 링크 또는 회사 웹사이트의 투자자 섹션을 통해 라이브 웹캐스트에 접속할 수 있습니다. 웹캐스트 녹화는 행사 후 최소 90일간 다시보기로 제공됩니다.
SI-BONE Inc (Nasdaq : SIBN), une entreprise de dispositifs médicaux spécialisée dans les troubles sacropelviens, a annoncé sa participation à la Conférence Santé BofA Securities 2025 à Las Vegas. La direction de la société animera une discussion informelle le 13 mai 2025 à 8h40 PT / 11h40 ET. Les investisseurs pourront accéder à la diffusion en direct via un lien d'inscription ou la section investisseurs du site web de l'entreprise. L'enregistrement de la diffusion restera disponible en replay pendant au moins 90 jours après l'événement.
SI-BONE Inc (Nasdaq: SIBN), ein Medizintechnikunternehmen mit Fokus auf sakropelvine Erkrankungen, hat seine Teilnahme an der 2025 BofA Securities Healthcare Conference in Las Vegas angekündigt. Die Geschäftsleitung des Unternehmens wird am 13. Mai 2025 um 8:40 Uhr PT/11:40 Uhr ET ein Gespräch am Kamin führen. Investoren können über einen Registrierungslink oder den Investor-Bereich der Unternehmenswebsite auf das Live-Webcast zugreifen. Die Aufzeichnung des Webcasts wird mindestens 90 Tage nach der Veranstaltung zum Nachsehen verfügbar sein.
- None.
- None.
SANTA CLARA, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 BofA Securities Healthcare Conference in Las Vegas. Management will be hosting a fireside chat on Tuesday, May 13, 2025, at 8:40 a.m. Pacific Time/11:40 a.m. Eastern Time.
Investors interested in listening to the conference call may do so by registering at this link: https://bofa.veracast.com/webcasts/bofa/healthcare2025/id92Nrrn.cfm. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.
About SI-BONE, Inc.
SI-BONE (NASDAQ: SIBN) is a global leader in developing unique technologies for surgical treatment of sacropelvic disorders. Since pioneering minimally invasive SI joint surgery in 2009, SI-BONE has supported over 4,500 physicians in performing a total of over 120,000 procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including two randomized controlled trials and over 160 peer reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, sacropelvic fixation and pelvic trauma.
For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.
iFuse Bedrock Granite, iFuse TORQ, iFuse TORQ TNT, SI-BONE, and iFuse INTRA are registered trademarks of SI-BONE, Inc. ©2025 SI-BONE, Inc. All Rights Reserved.
Investor Contact: Saqib Iqbal investors@si-bone.com
FAQ
When is SI-BONE (SIBN) presenting at the BofA Securities Healthcare Conference 2025?
How can investors access SI-BONE's (SIBN) presentation at the BofA Healthcare Conference?
How long will SI-BONE's (SIBN) BofA Healthcare Conference webcast be available for replay?
What does SI-BONE (SIBN) specialize in as a medical device company?
